ImaginAb
Clinically manages cancer and autoimmune diseases via molecular imaging by re-engineering antibodies into small proteins.
Launch date
Employees
Market cap
-
Enterprise valuation
$51—77m (Dealroom.co estimates Jun 2021.)
Inglewood California (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$12.5m | Series A | ||
$21.0m | Series B | ||
N/A | $5.3m | Late VC | |
$8.0m | Late VC | ||
$12.8m | Late VC | ||
Total Funding | $59.6m |
Recent News about ImaginAb
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.